Your shopping cart is currently empty

YM-344031 is an orally administered antagonist targeting CCR3. It effectively inhibits the binding of Eotaxin-1 and RANTES to CCR3, with IC50 values of 3.0 and 16.3 nM, respectively. YM-344031 also suppresses ligand-induced increases in intracellular Ca [2+] levels and chemotaxis, alters eosinophil morphology induced by eotaxin-1 in macaque blood, and prevents allergic skin reactions in a mouse allergy model.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | YM-344031 is an orally administered antagonist targeting CCR3. It effectively inhibits the binding of Eotaxin-1 and RANTES to CCR3, with IC50 values of 3.0 and 16.3 nM, respectively. YM-344031 also suppresses ligand-induced increases in intracellular Ca [2+] levels and chemotaxis, alters eosinophil morphology induced by eotaxin-1 in macaque blood, and prevents allergic skin reactions in a mouse allergy model. |
| Molecular Weight | 502.58 |
| Formula | C29H31FN4O3 |
| Cas No. | 671204-98-1 |
| Smiles | C(C1=CC2=C(C=C1)C=C(F)C=C2)N3C[C@H](NC(C=C4CCN(C(=O)C5=C(C)C=CC=N5=O)CC4)=O)CC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.